Behavioral Activation Therapy Cuts Perinatal Suicide Risk
In a study of 1117 perinatal adults receiving behavioral activation therapy, the odds of endorsing suicide ideation decreased by 25% with each treatment session and by 80% at 3 months post-randomization, with specialist and nonspecialist providers showing equal effectiveness.
METHODOLOGY:
A multisite, noninferiority, four-arm randomized clinical trial called the Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) compared clinicians (nonspecialist vs specialist) and modalities (telemedicine vs in-person) in delivering behavioral activation therapy.
Research was conducted at university-affiliated networks in Chicago, Illinois; Chapel Hill, North Carolina; and Toronto, Ontario, Canada.
Participants included pregnant (≤ 36 weeks) and postpartum (4-30 weeks) adults with depressive symptoms (Edinburgh Postnatal Depression Scale score ≥ 10).
A total of 1117 participants who completed at least one treatment session and provided ≥ 1 week of Edinburgh Postnatal Depression Scale data were included in the analysis.
Treatment consisted of a manualized 6- to 8-session perinatal behavioral activation intervention delivered weekly.
TAKEAWAY:
Among 1230 enrolled pregnant and postpartum adults, 1117 completed at least one treatment session, with 264 (23.6%) endorsing suicide ideation during treatment.
The odds of endorsing suicide ideation decreased by 25% with each additional treatment session (odds ratio [OR], 0.75; 95% CI, 0.58-0.96; P = .03).
At 3 months post-randomization, the odds of endorsing suicide ideation decreased by 80% compared with any time during treatment (OR, 0.20; 95% CI, 0.14-0.27; P < .001).
No significant differences were found in the odds of endorsing suicide ideation between clinician types (nonspecialist vs specialist) or delivery modalities (telemedicine vs in person).
IN PRACTICE:
'Behavioral activation is a first-line recommended treatment for perinatal depression and may reduce postpartum suicide risk by increasing values-consistent living and awareness of ineffective behaviors,' wrote the authors of the study.
SOURCE:
The study was led by Parisa Kaliush, PhD, Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, and Daisy Singla, PhD, Centre for Addiction and Mental Health in Toronto. It was published online in JAMA Psychiatry.
LIMITATIONS:
High suicide risk prompted exclusion from SUMMIT trial, and the final sample was highly educated, suggesting some limitations in generalizability. However, the prevalence of suicide ideation at baseline (15.0%) was higher than previously cited rates.
DISCLOSURES:
This study was funded by the Patient-Centered Outcomes Research Institute. Bradley Gaynes, PhD, disclosed receiving compensation for authorship/review of UpToDate chapters on depression. Samantha Meltzer-Brody, MD, MPH, reported receiving research funding to the University of North Carolina for clinical trials sponsored by Sage Therapeutics, Electromedical Products International, and Sirtsei Pharmaceuticals, serving as a clinical advisor and professional corporation owner for Modern Health, and serving as a scientific advisor to EmbarkNeuro and Seaport Therapeutics. Simone Vigod, MD, disclosed receiving royalties from UpToDate for authorship of materials on depression and pregnancy.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Wire
2 hours ago
- Geek Wire
B.C. healthy longevity company Molecular You raises $5M to expand biomarker testing
The Molecular You platform measures 250 biomarkers. (Molecular You Photo) Molecular You, a Vancouver, B.C., healthy longevity company, announced today that it has raised $5 million from investors. The company offers testing for a slate of 250 biomarkers that can provide insights into an individual's potential risk for ailments including cardiovascular disease, diabetes, dementia, irritable bowel syndrome and others. The analysis requires a blood sample and is available in the U.S. via online sales direct-to-consumer and in Canada at partner clinics. 'We plan to use this capital to grow our customer base across both consumer and clinical channels in North America, while also continuing to expand the platform's analysis and predictive capabilities,' said Jim Kean, CEO of Molecular You, in a statement. Jim Kean, CEO of Molecular You. (Molecular You Photo) The biomarker panel costs $1,099 in the U.S. and the test includes an in-home appointment for a blood draw at no additional charge. In Canada, the service costs $1,149 and blood is drawn at locations such as LifeLabs, Dynacare and others. The testing and analysis are not covered by insurance. In the near future, Molecular You aims to expand its panel to more than 800 biomarkers through the use of 'next-generation multi-omic assays' which include biological molecules such as RNA transcripts, proteins and metabolites. 'This will enable higher-resolution analysis and broaden the platform's scope to additional areas, including certain cancers,' the company said in a release. Molecular You launched in 2014 as a spinoff from Canada's Personalized Medicine Initiative and has 25 employees. The company is part of the growing longevity sector, which includes services such as full-body MRIs used to look for early signs of cancer or other issues; genomic sequencing; plasma exchange; and imaging of coronary arteries. Longevity tech attracted $1.8 billion in investments from 2021 through the first quarter of this year, according to PitchBook. While the field's focus was once on age-related ailments such as cardiovascular and neurological diseases, it's turning to biological factors associated with aging and extending lifespans, PitchBook noted. Circulate Health, a Seattle-based healthy longevity startup providing plasma exchange, announced $12 million in seed funding last month. Molecular You's Series A investment round was led by Voloridge Health with participation from Dynamic Leap and others. The company has raised $29 million in total. Its co-founders include Rob Fraser, president and chief scientist; David Wishart, chief informatics officer; Christoph Borchers, chief lab analytics officer; Haiyan Yang, vice president of operations; and Ash Anwar, senior director of data science.
WebMD
2 hours ago
- WebMD
The Real Risks of Turning to AI for Therapy
Aug. 20, 2025 — Whenever Luke W Russell needs to work through something, they turn to ChatGPT. (Luke uses they/them pronouns.) 'I've wept as I've navigated things,' said the Indianapolis filmmaker, who uses the chatbot to pick apart intrusive thoughts or navigate traumatic memories. 'I've had numerous times when what ChatGPT is saying to me is so real, so powerful, and I feel so deeply seen.' Russell's experience reflects a broader, growing reality: Many people are turning to chatbots for mental health support — for everything from managing anxiety and processing grief to coping with work conflicts and defusing marital spats. More than half of adults ages 18-54 — and a quarter of adults 55 and up — say they would be comfortable talking with an AI chatbot about their mental health, according to a 2025 survey by the Harris Poll and the American Psychological Association (APA). The catch: OpenAI's ChatGPT and other chatbots — like Anthropic's Claude and Google's Gemini — are not designed for this. Even AI products promoted as emotional health tools — like Replika, Wysa, Youper, and MindDoc — were not built on validated psychological methods, said psychologist C. Vaile Wright, PhD, senior director of the APA's Office of Health Care Innovation. 'I would argue that there isn't really any commercially approved, AI-assisted therapy at the moment,' said Wright. 'You've got a whole lot of chatbots where there is no research, there's no psychological science, and there are no subject matter experts.' Critics warn that AI's potential for bias, lack of true empathy, and limited human oversight could actually endanger users' mental health, especially among vulnerable groups like children, teens, people with mental health conditions, and those experiencing suicidal thoughts. The growing concern has led to the emergence of the terms 'ChatGPT psychosis' or ' AI psychosis ' — referring to the potential harmful mental health effects of interacting with AI. It's even drawing attention from lawmakers: This month, Illinois enacted restrictions on AI in mental health care, banning its use for therapy and prohibiting mental health professionals from using AI to communicate with clients or make therapeutic decisions. (Similar restrictions have already been passed in Nevada and Utah.) But none of this is stopping people from turning to chatbots for support, especially amid clinician shortages, rising therapy costs, and inadequate mental health insurance coverage. 'People have absolutely reported that experiences with chatbots can be helpful,' said Wright. The Draw of Chatbots for Mental Health Data shows we're facing a massive shortage of mental health workers, especially in remote and rural areas, said psychologist Elizabeth Stade, PhD, a researcher in the Computational Psychology and Well-Being Lab at Stanford University in Stanford, CA. 'Of adults in the United States with significant mental health needs, only about half are able to access any form of treatment. With youth, that number is closer to 75%,' said Jessica Schleider, PhD, a child and adolescent psychologist at Northwestern University in Chicago. 'The provider shortage is clearly contributing to why so many folks are turning to their devices and, now increasingly, to generative AI to fill that gap.' Unlike a therapist, a chatbot is available 24/7. 'When [people] need help the most, it is typically after hours,' said Wright, who suggested the right AI tool could potentially supplement human therapy. 'When it's 2 a.m. and you're in crisis, could this help provide some support?' Probably, she said. Results of the first clinical trial of an AI-generative therapy chatbot showed 'significant, clinically meaningful reductions in depression, anxiety, and eating disorder symptoms' within four to eight weeks, said lead study author Michael V. Heinz, MD, a professor at Dartmouth College's Geisel School of Medicine and faculty affiliate at the Center for Technology and Behavioral Health in Lebanon, New Hampshire. The chatbot — Therabot, developed at Dartmouth — combines extensive training in evidence-based psychotherapy interventions with advanced generative AI. 'We saw high levels of user engagement — six-plus hours on average across the study,' Heinz said. Participants said using Therabot was like talking to a human therapist. But results are early, and more studies are needed, Heinz said. Access and affordability drew Russell to ChatGPT, they said. 'I didn't set out to use ChatGPT as a therapist. I quit therapy in January due to income dropping. I was already using ChatGPT on the regular for work, and then I started using it for personal idea exploration. ... I've never had a therapist who could move as fast as ChatGPT and ignore miscellaneous things,' they said. Perhaps one of the most appealing aspects is that chatbots don't judge. 'People are reluctant to be judged, and so they are often reluctant to disclose symptoms,' said Jonathan Gratch, PhD, professor of computer science and psychology at the University of Southern California, who has researched the topic. One of his studies found that military veterans were more likely to share PTSD symptoms with a virtual chatbot than in a survey. When Chatbots Are Harmful Most people don't know how AI works — they might believe it's always objective and factual, said Henry A. Willis, PhD, a psychologist and professor at the University of Maryland in College Park. But often, the data they're trained on is not representative of minority groups, leading to bias and technology-mediated racism, Willis said. 'We know that Black and brown communities are not adequately reflected in the majority of large-scale mental health research studies,' Willis said. So a chatbot's clinical symptom information or treatment recommendations may not be relevant or helpful to those from minority backgrounds. There's also an impersonal aspect. Chatbots do what's called ecological fallacy, said H. Andrew Schwartz, PhD, associate professor of computer science at Stony Brook University in Stony Brook, NY. They treat scattered comments like random data points, making assumptions based on group-level data that may not reflect the reality of individuals. And who's accountable if something goes wrong? Chatbots have been linked to cases involving suggestions of violence and self-harm, including the death of a teen by suicide. Some chatbots marketed for companionship and emotional support were designed with another incentive: to make money. Wright is concerned that they may unconditionally validate patients, telling them what they want to hear so they stay on the platform — 'even if what they're telling you is actually harmful or they're validating harmful responses from the user.' None of these conversations are bound by HIPAA regulations, either, Wright pointed out. 'So even though they may be asking for personal information or sharing your personal information, they have no legal obligation to protect it.' The Psychological Implications of Forming Emotional Bonds With AI In an opinion article published in April in the journal Trends in Cognitive Sciences, psychologists expressed concern about the long-term implications of forming emotional bonds with AI. Chatbots can replace users' real relationships, crowding out romantic partners, co-workers, and friends. This may mean that individuals begin to 'trust' the opinion and feedback of chatbots over real people, said Willis. 'The ongoing positive reinforcement that can happen instantly from interacting with a chatbot may begin to overshadow any reinforcement from interacting with real people,' who may not be able to communicate as quickly, he said. 'These emotional bonds may also impair people's ability to have a healthy level of skepticism and critical evaluation skills when it comes to the responses of AI chatbots.' Gratch compared it to hunger and food. 'We're biologically wired to seek out food when we get hungry. It is the same with social relationships. If we haven't had a relationship in a while, we may feel lonely, and then that motivates us to go out and reach out to people.' But studies suggest that social interaction with a computer program, like a chatbot, can sate a person's social needs and demotivate them to go out with friends, he said. 'That may have long-term consequences for increased loneliness. For example, research has shown people who compulsively use Facebook tend to be much more lonely.' Counseling with a therapist involves 'a natural curiosity about the individual and their experiences that AI cannot replicate,' Willis said. 'AI chatbots respond to prompts, whereas therapists can observe and ask clinical questions based on one's body language, a synthesis of their history, and other things that may not be conscious to the client — or things the client may not even be aware are important to their mental health well-being.' The Future of AI Therapy "I think there is going to be a future where you have really well-developed [chatbots] for addressing mental health that are scientifically driven and where they are ensuring that there are guardrails in place when somebody is in crisis. We're just not quite there yet,' said the APA's Wright. 'We may get to a place where they're even reimbursed by insurance,' she said. 'I do think increasingly we are going to see providers begin to adopt these technology tools as a way to meet their patients' needs.' But for now, her message is clear: The chatbots are not there yet. 'Ideally, chatbot design should encourage sustained, meaningful interaction with the primary purpose of delivering evidence-based therapy,' said Dartmouth's Heinz. Until then, don't rely on them too heavily, the experts cautioned — and remember, they are not a substitute for professional help.
Yahoo
5 hours ago
- Yahoo
Health Matters: Crown Royal whisky recalled due to possible glass in bottles
The Canadian Food Inspection Agency is recalling several lots of 12 year old Canadian whisky due to a possible presence of glass in the beverage. The agency says 750ml bottles of Crown Royal Reserve brand whiskey are being pulled from shelves in Newfoundland and Labrador, Alberta, B.C., and Ontario. Katherine Ward has this story and more in Health Matters for Aug. 20, 2025.
